Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

02/09/2015 - 3 minutes

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked.

In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. Excess phosphate in circulation can be a result of renal failure and certain endocrine disorders. If allowed to accumulate, it can cause various other imbalances, including hypocalcemia,  therefore resulting in conditions such as renal osteodystrophy.

Tenapanor works as an inhibitor of phosphate carrier molecules, such as the NaP2b protein, which is primarily expressed in the upper intestinal tract.  Its safety is partly attributed to its ability to remain within the lumen of the gut without absorption, up to 98% of which is eventually excreted (as shown in rats). It has been developed as a treatment for chronic kidney disease patients on dialysis, end-stage renal disease (ESRD) and also irritable bowel syndrome (specifically IBS-C).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!